Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.48 |
| ▸ | PDE4A | P27815 | 10/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71039 | 0.85 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CSCN9A | |
| SCHEMBL72712 | 0.83 | SCN9A (0.46) | PDE4DPDE4BPDE4APDE4CSCN9A | |
| SCHEMBL26814565 | 0.82 | SCN9A (0.46) | PDE4DPDE4BPDE4APDE4CSCN9A | |
| SCHEMBL72129 | 0.81 | KDM4E (0.38) | SCN9APOLBMEN1KMT2A | |
| SCHEMBL7360312 | 0.78 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL26814564 | 0.78 | PDE5A (0.45) | PDE4DPDE4BPDE4APDE4CSCN9A | |
| SCHEMBL20772341 | 0.76 | NR1I2 (0.40) | SCN9APOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL70953 | 0.76 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4CSCN9A | |
| SCHEMBL72303 | 0.76 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4CSCN9A | |
| SCHEMBL20775395 | 0.75 | SOS1 (0.40) | POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0711282-B1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | AVENTIS PHARMA LTD (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.